The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib ... This new indication also applies to Kisqali Femara Co-Pack (ribociclib with letrozole). The approval was based on data ...

drug maker Novartis announced Tuesday. “The FDA approval of Kisqali for this early breast cancer population, including those ...

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, ...

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The vast majority of adults 65 and older living in the United States take prescription medication to manage their health ...

Members of my lab are interested in how hormones act in the brain to influence response to drugs of abuse. This student was engaged in primarily archival research on this topic. During her time ...

A medication that is currently used for chronic kidney disease in patients with type 2 diabetes has been found to reduce the risk of worsening heart failure and cardiovascular death in certain ...